To investigate whether the Integrin αvβ3/ERK1/2/GLI1 pathway regulates the stem cell-like characteristics of gastric cancer MCAs, Integrin αvβ3 inhibitor Cilengitide, ERK inhibitor PD-184161, GLI1 inhibitor GANT61 and a blank control DMSO were added into BGC823 MCAs and SGC7901 MCAs. This evidence concerns the gene MAPK3 and gastric cancer.